These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 32147909)

  • 21. Comparative Epigenetic Profiling Reveals Distinct Features of Mucosal Melanomas Associated with Immune Cell Infiltration and Their Clinical Implications.
    Dai J; Jia J; Zhang F; Liu K; Xi Y; Yuan P; Mao L; Bai X; Wei X; Wang B; Li J; Xu Y; Liu T; Chang S; Shao Y; Guo J; Ying J; Si L
    Cancer Res Commun; 2024 May; 4(5):1351-1362. PubMed ID: 38695555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epigenetically reprogramming metastatic tumor cells with an embryonic microenvironment.
    Costa FF; Seftor EA; Bischof JM; Kirschmann DA; Strizzi L; Arndt K; Bonaldo Mde F; Soares MB; Hendrix MJ
    Epigenomics; 2009 Dec; 1(2):387-98. PubMed ID: 20495621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA Methylation Levels of Melanoma Risk Genes Are Associated with Clinical Characteristics of Melanoma Patients.
    de Araújo ÉS; Pramio DT; Kashiwabara AY; Pennacchi PC; Maria-Engler SS; Achatz MI; Campos AH; Duprat JP; Rosenberg C; Carraro DM; Krepischi AC
    Biomed Res Int; 2015; 2015():376423. PubMed ID: 26106605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic silencing of the PTEN gene in melanoma.
    Mirmohammadsadegh A; Marini A; Nambiar S; Hassan M; Tannapfel A; Ruzicka T; Hengge UR
    Cancer Res; 2006 Jul; 66(13):6546-52. PubMed ID: 16818626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.
    Hoon DS; Spugnardi M; Kuo C; Huang SK; Morton DL; Taback B
    Oncogene; 2004 May; 23(22):4014-22. PubMed ID: 15064737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genome-wide promoter methylation analysis identifies epigenetic silencing of MAPK13 in primary cutaneous melanoma.
    Gao L; Smit MA; van den Oord JJ; Goeman JJ; Verdegaal EM; van der Burg SH; Stas M; Beck S; Gruis NA; Tensen CP; Willemze R; Peeper DS; van Doorn R
    Pigment Cell Melanoma Res; 2013 Jul; 26(4):542-54. PubMed ID: 23590314
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of SRGN in the survival and immune infiltrates of skin cutaneous melanoma (SKCM) and SKCM-metastasis patients.
    Wang X; Xiong H; Liang D; Chen Z; Li X; Zhang K
    BMC Cancer; 2020 May; 20(1):378. PubMed ID: 32370744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant CpG methylation of the TFAP2A gene constitutes a mechanism for loss of TFAP2A expression in human metastatic melanoma.
    Hallberg AR; Vorrink SU; Hudachek DR; Cramer-Morales K; Milhem MM; Cornell RA; Domann FE
    Epigenetics; 2014 Dec; 9(12):1641-7. PubMed ID: 25625848
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MMP-9 overexpression is associated with intragenic hypermethylation of MMP9 gene in melanoma.
    Falzone L; Salemi R; Travali S; Scalisi A; McCubrey JA; Candido S; Libra M
    Aging (Albany NY); 2016 May; 8(5):933-44. PubMed ID: 27115178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma.
    Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
    EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Revisiting the Clinical and Biologic Relevance of Partial PTEN Loss in Melanoma.
    Giles KM; Rosenbaum BE; Berger M; Izsak A; Li Y; Illa Bochaca I; Vega-Saenz de Miera E; Wang J; Darvishian F; Zhong H; Osman I
    J Invest Dermatol; 2019 Feb; 139(2):430-438. PubMed ID: 30148988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucosal melanomas of different anatomic sites share a common global DNA methylation profile with cutaneous melanoma but show location-dependent patterns of genetic and epigenetic alterations.
    Jurmeister P; Wrede N; Hoffmann I; Vollbrecht C; Heim D; Hummel M; Wolkenstein P; Koch I; Heynol V; Schmitt WD; Thieme A; Teichmann D; Sers C; von Deimling A; Thierauf JC; von Laffert M; Klauschen F; Capper D
    J Pathol; 2022 Jan; 256(1):61-70. PubMed ID: 34564861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive analysis of prognostic immune-related genes in the tumor microenvironment of cutaneous melanoma.
    Yang S; Liu T; Nan H; Wang Y; Chen H; Zhang X; Zhang Y; Shen B; Qian P; Xu S; Sui J; Liang G
    J Cell Physiol; 2020 Feb; 235(2):1025-1035. PubMed ID: 31240705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy.
    Niebel D; Fröhlich A; Zarbl R; Fietz S; de Vos L; Vogt TJ; Dietrich J; Sirokay J; Kuster P; Saavedra G; Ramírez Valladolid S; Hoffmann F; Strieth S; Landsberg J; Dietrich D
    Clin Epigenetics; 2022 Apr; 14(1):50. PubMed ID: 35410311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome.
    Garg K; Maurer M; Griss J; Brüggen MC; Wolf IH; Wagner C; Willi N; Mertz KD; Wagner SN
    Hum Pathol; 2016 Aug; 54():157-64. PubMed ID: 27107457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transposable hypomethylation is associated with metastatic capacity of primary melanomas.
    Ecsedi SI; Hernandez-Vargas H; Lima SC; Herceg Z; Adany R; Balazs M
    Int J Clin Exp Pathol; 2013; 6(12):2943-8. PubMed ID: 24294382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells.
    Lee YK; Park UH; Kim EJ; Hwang JT; Jeong JC; Um SJ
    Cancer Lett; 2017 Sep; 403():144-151. PubMed ID: 28634046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of the treatment-naive immune microenvironment in melanoma with
    Wang M; Zadeh S; Pizzolla A; Thia K; Gyorki DE; McArthur GA; Scolyer RA; Long G; Wilmott JS; Andrews MC; Au-Yeung G; Weppler A; Sandhu S; Trapani JA; Davis MJ; Neeson PJ
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35383113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Targeted Quantitative Proteomic Approach Assesses the Reprogramming of Small GTPases during Melanoma Metastasis.
    Huang M; Qi TF; Li L; Zhang G; Wang Y
    Cancer Res; 2018 Sep; 78(18):5431-5445. PubMed ID: 30072397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Correlative study of epigenetic regulation of tumor microenvironment in spindle cell melanomas and cutaneous malignant peripheral nerve sheath tumors.
    Vougiouklakis T; Aung PP; Vasudevaraja V; Prieto VG; Torres-Cabala CA; Sulman EP; Snuderl M; Jour G
    Sci Rep; 2020 Aug; 10(1):12996. PubMed ID: 32747660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.